Cargando…

Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease

Glucosylceramide and glucosylsphingosine are the two major storage products in Gaucher disease (GD), an inherited metabolic disorder caused by a deficiency of the lysosomal enzyme glucocerebrosidase. The build-up of glucosylceramide in the endoplasmic reticulum and prominent accumulation in cell lys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lukas, Jan, Cozma, Claudia, Yang, Fan, Kramp, Guido, Meyer, Anja, Neßlauer, Anna-Maria, Eichler, Sabrina, Böttcher, Tobias, Witt, Martin, Bräuer, Anja U., Kropp, Peter, Rolfs, Arndt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666873/ https://www.ncbi.nlm.nih.gov/pubmed/29053611 http://dx.doi.org/10.3390/ijms18102192

Ejemplares similares

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
por: Rolfs, Arndt, et al.
Publicado: (2013)

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
por: Dinur, Tama, et al.
Publicado: (2021)

Diagnosis of Morquio Syndrome in Dried Blood Spots Based on a New MRM-MS Assay
por: Cozma, Claudia, et al.
Publicado: (2015)

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
por: Dinur, Tama, et al.
Publicado: (2022)

Glucosylsphingosine (Lyso-Gb(1)): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease
por: Gayed, Matthew M., et al.
Publicado: (2022)

Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
por: Cozma, Claudia, et al.
Publicado: (2020)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
por: Stiles, Ashlee R., et al.
Publicado: (2021)

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
por: Giuffrida, Gaetano, et al.
Publicado: (2023)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Olfactory Performance as an Indicator for Protective Treatment Effects in an Animal Model of Neurodegeneration
por: Meyer, Anja, et al.
Publicado: (2018)

A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1
por: Neßlauer, Anna-Maria, et al.
Publicado: (2019)

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
por: Charkhand, Behshad, et al.
Publicado: (2019)

C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
por: Cozma, Claudia, et al.
Publicado: (2017)

An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan
por: Ida, Hiroyuki, et al.
Publicado: (2022)

Genetic characterization of the Albanian Gaucher disease patient population
por: Cullufi, Paskal, et al.
Publicado: (2020)

Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1
por: Srikanth, Manasa P., et al.
Publicado: (2021)

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2019)

Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.
por: Lelieveld, Lindsey T., et al.
Publicado: (2022)

Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells
por: Stahl-Meyer, Kamilla, et al.
Publicado: (2022)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
por: Symeonidis, Argiris, et al.
Publicado: (2023)

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk
por: Becker-Cohen, Michal, et al.
Publicado: (2022)

A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease
por: Giese, Anne-Katrin, et al.
Publicado: (2015)

Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann–Pick-Disease Type C1
por: Ebner, Lynn, et al.
Publicado: (2018)

Optic Nerve Lipidomics Reveal Impaired Glucosylsphingosine Lipids Pathway in Glaucoma
por: Chauhan, Muhammad Zain, et al.
Publicado: (2019)

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021)

Olfactory Deficits in Niemann-Pick Type C1 (NPC1) Disease
por: Hovakimyan, Marina, et al.
Publicado: (2013)

Increased Regenerative Capacity of the Olfactory Epithelium in Niemann–Pick Disease Type C1
por: Meyer, Anja, et al.
Publicado: (2017)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Images from the Haematologica Atlas of Hematologic Cytology: Gaucher disease
por: Invernizzi, Rosangela
Publicado: (2022)

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
por: Stirnemann, Jérôme, et al.
Publicado: (2017)

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
por: Curado, Filipa, et al.
Publicado: (2023)

A rare homozygous p.Arg87Trp variant of the GBA gene in Gaucher disease: A case report
por: Jilani, Houweyda, et al.
Publicado: (2022)

Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy
por: Kim, Yoon-Myung, et al.
Publicado: (2020)

A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry
por: Van Baelen, Amber, et al.
Publicado: (2023)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Identification of Brain-Specific Treatment Effects in NPC1 Disease by Focusing on Cellular and Molecular Changes of Sphingosine-1-Phosphate Metabolism
por: Gläser, Anne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jk0n233382c9c5callcpg0hca8